Back to browse

EXP001464

Paper

Targeted gene silencing in human embryonic stem cells using cell-penetrating peptide PepFect 14 (2019)

Peptide

PepFect 14 (PF14)

Sequence: stearyl-AGYLLGKLLOOLAAAALOOLL-NH2

RNA

siRNA

All experiment fields

Experiment Id EXP001464
Paper Targeted gene silencing in human embryonic stem cells using cell-penetrating peptide PepFect 14
Peptide PepFect 14 (PF14)
Delivery Success Class no
In Vivo Flag no
Uptake Confirmed yes
Label Confidence high
In Vitro Functional Effect yes
Endosomal Escape Evidence
Peptide Concentration Set by CR 2:1 and MR 16:1 (peptide:siRNA); PF14 stock 100 µM used. (Exact µM peptide depends on siRNA concentration.)
Rna Concentration 10–30 nM siB2M (tested 10, 20, 30 nM)
Mixing Ratio Complexes formed in 200 µL (1/10 final transfection volume) for 1 h at room temperature; adjusted to charge ratio (CR/N:P) 2:1 and molar ratio (MR) 16:1 (peptide:siRNA).
Formulation Format PF14/siRNA nanocomplexes (noncovalent electrostatic nanoparticles)
Formulation Components PepFect 14 (PF14) + siRNA (targeted or control) in mTeSR1 medium; Transfection performed immediately after EDTA passaging and plating hES cells as small clumps in mTeSR1 + ROCK inhibitor (Y-27632, 10 µM). Complexes kept in medium 24 h, then medium exchanged.
Size Nm
Zeta Mv
Model Scope in_vitro
Model Type in vitro
Cell Lines Or Primary Cells Human embryonic stem cells: H9 (WA09)
Animal Model
Administration Route
Output Type In vitro functional effect: B2M knockdown (flow cytometry protein; RT-qPCR mRNA) at 48–72 h
Output Value
Output Units
Output Notes Protein: ~33% reduction at 48 h with 10 nM; ~40% reduction at 48 h with 20–30 nM; partial recovery by 72 h (~25% reduction). mRNA: at 20 nM, ~75% reduction at 48 h and ~45% at 72 h.
Toxicity Notes Cell viability decreased at higher siRNA/PF14 doses (30 nM), while 10–20 nM maintained viability close to untreated controls (cell count at 72 h).
Curation Notes